About IONETIX:
IONETIX is a US-based cyclotron and technology company founded in 2009. Utilizing a proprietary cyclotron technology platform, Ionetix is focused on developing innovative accelerator solutions for the production and distribution of radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. Ionetix offers turnkey services for the point-of-care supply of the diagnostic positron emission tomography (PET) radiopharmaceutical N-13 Ammonia. Ionetix is now expanding its services to include the supply of therapeutic alpha isotopes used in radiopharmaceuticals being developed to treat various cancers. Located in Lansing, Michigan, Ionetix is establishing the first dedicated alpha isotope manufacturing and distribution facility to produce alpha isotopes Astatine-211 (At-211) and Actinium-225 (Ac-225).

About Precision Molecular, Inc.:
Precision Molecular, Inc. (PMI) is a clinical-stage company with the mission to develop targeted radiopharmaceuticals for the treatment and management of patients with cancer. PMI is developing multiple targeted alpha-particle therapies for a broad range of solid tumors targeting PSMA, Fibroblast Activation Protein (FAP) and Carbonic anhydrase IX as well as advancing a number of imaging biomarker products in the clinic with great potential to improve early diagnosis of cancer. PMI is a subsidiary of D&D Pharmatech; a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty and biotechnology veterans. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients.


SOURCE IONETIX

Back to HCB News

Molecular Imaging Homepage